A compound of formula (II), a tautomer thereof or a pharmaceutically acceptable salt thereof, and use thereof in the preparation of medicaments for treating solid tumor-related diseases. ##STR00001##

The present invention provides a novel compound that has anti-RSV activity and that is useful in the prevention or treatment of an infection in which viruses of the subfamily Pneumovirinae, including respiratory syncytial virus (RSV), are involved, or a pharmaceutically acceptable salt thereof. Specifically, the present invention provides a compound represented by formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of FGFR enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with FGFR signaling with the compounds and compositions of the disclosure.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of FGFR enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with FGFR signaling with the compounds and compositions of the disclosure.

The present invention provides compounds, compositions thereof, and methods of using the same.

Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The disclosure further relates to methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof.

Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The disclosure further relates to methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof.

The present invention provides use of an ionization radiation source in preparation of a porous crystalline material, and a method for preparing a MOFs material and a COFs material. In the present invention, the ionization radiation source is used for preparing the porous crystalline material; under the irradiation of the ionization radiation source, the porous crystalline material (MOFs, COFs) can be synthesized in an extremely short time, wherein the ionization radiation source is used for providing energy required in a reaction for preparing the porous crystalline material. The preparation process does not need heating, so that energy consumption is reduced and a high-pressure system is avoided. The aforementioned preparation method is simple, low in instrument and equipment cost, and thus is a environmentally friendly and extremely low-cost synthesis method.

The present invention provides a compound represented by Formula (I): ##STR00001##
wherein ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring or the like; R.sup.1 is halogen or the like; R.sup.2a and R.sup.2b are each independently hydrogen or the like; R.sup.3 is substituted or unsubstituted alkyl or the like; R.sup.4 is hydrogen or the like; and n is an integer of 1 to 3.

The present invention provides a compound represented by Formula (I): ##STR00001##
wherein ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring or the like; R.sup.1 is halogen or the like; R.sup.2a and R.sup.2b are each independently hydrogen or the like; R.sup.3 is substituted or unsubstituted alkyl or the like; R.sup.4 is hydrogen or the like; and n is an integer of 1 to 3.